| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $13.1M | +29.8% |
| Cost of Revenue | $6.6M | -14.5% |
| R&D Expense | $44.5M | +11.3% |
| SG&A Expense | $87.7M | +118.7% |
| Operating Income | -$125.7M | +8.0% |
| Net Income | -$124.0M | +4.6% |
| EPS (Basic) | -$14.57 | +91.7% |
| EPS (Diluted) | -$14.57 | +91.7% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $207.6M | +110.2% |
| Accounts Receivable | $6.3M | +70.3% |
| Current Assets | $228.9M | +92.3% |
| Total Assets | $277.2M | +70.2% |
| Current Liabilities | $30.8M | +68.4% |
| Long-term Debt | $8.7M | +0.0% |
| Total Liabilities | $32.0M | +37.2% |
| Stockholders' Equity |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$99.8M | -63.9% |
| Capital Expenditures | $3.4M | +2707.5% |
| Investing Cash Flow | -$4.5M | -3673.3% |
| Financing Cash Flow | $214.5M | +59.1% |
| Free Cash Flow | -$103.2M | -69.1% |
| $245.2M |
| +75.7% |